This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cunningham, J. M. Articles by Thibodeau, S. N. Search for Related Content PubMed PubMed Citation Articles by Cunningham, J. M. Articles by Thibodeau, S. N.

Evaluation of Genetic Variations in the Androgen and Estrogen Metabolic Pathways as Risk Factors for Sporadic and Familial Prostate Cancer

¹ Department of Laboratory Medicine and Pathology, ² Division of Biostatistics, ³ Department of Health Sciences Research, and ⁴ Department of Urology, Mayo Clinic and Foundation, Rochester, Minnesota

Requests for reprints: Stephen N. Thibodeau, Mayo Clinic, 200 First Street Southwest, 920 Hilton Building, Rochester, MN 55905. Phone: 507-284-9185; Fax: 507-284-0670. E-mail: sthibodeau{at}mayo.edu

Previous studies suggest that enzymes involved in the androgen metabolic pathway are susceptibility factors for prostate cancer. Estrogen metabolites functioning as genotoxins have also been proposed as risk factors. In this study, we systematically tested the hypothesis that common genetic variations for those enzymes involved in the androgen and estrogen metabolic pathways increase risk for sporadic and familial prostate cancer. From these two pathways, 46 polymorphisms (34 single nucleotide polymorphisms, 10 short tandem repeat polymorphisms, and 2 null alleles) in 25 genes were tested for possible associations. Those genes tested included PRL, LHB, CYP11A1, HSD3B1, HSD3B2, HSD17B2, CYP17, SRD5A2, AKR1C3, UGT2B15, AR, SHBG, and KLK3 from the androgen pathway and CYP19, HSD17B1, CYP1A1, CYP1A2, CYP1B1, COMT, GSTP1, GSTT1, GSTM1, NQO1, ESR1, and ESR2 from the estrogen pathway. A case-control study design was used with two sets of cases: familial cases with a strong prostate cancer family history (n = 438 from 178 families) and sporadic cases with a negative prostate cancer family history (n = 499). The controls (n = 493) were derived from a population-based collection. Our results provide suggestive findings for an association with either familial or sporadic prostate cancer with polymorphisms in four genes: AKR1C3, HSD17B1, NQO1, and GSTT1. Additional suggestive findings for an association with clinical variables (disease stage, grade, and/or node status) were observed for single nucleotide polymorphisms in eight genes: HSD3B2, SRD5A2, SHBG, ESR1, CYP1A1, CYP1B1, GSTT1, and NQO1. However, none of the findings were statistically significant after appropriate corrections for multiple comparisons. Given that the point estimates for the odds ratio for each of these polymorphisms are <2.0, much larger sample sizes will be required for confirmation. (Cancer Epidemiol Biomarkers Prev 2007;16(5):969–78)

This article has been cited by other articles:

				J. D. Figueroa, N. Malats, M. Garcia-Closas, F. X. Real, D. Silverman, M. Kogevinas, S. Chanock, R. Welch, M. Dosemeci, Q. Lan, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes Carcinogenesis, October 1, 2008; 29(10): 1955 - 1962. [Abstract] [Full Text] [PDF]

				C. L. Pearce, D. J. Van Den Berg, N. Makridakis, J. K.V. Reichardt, R. K. Ross, M. C. Pike, L. N. Kolonel, and B. E. Henderson No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned Hum. Mol. Genet., August 15, 2008; 17(16): 2456 - 2461. [Abstract] [Full Text] [PDF]

				Z. Kote-Jarai, D. F. Easton, J. L. Stanford, E. A. Ostrander, J. Schleutker, S. A. Ingles, D. Schaid, S. Thibodeau, T. Dork, D. Neal, et al. Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2052 - 2061. [Abstract] [Full Text] [PDF]

				M. H. McIntyre, P. W. Kantoff, M. J. Stampfer, L. A. Mucci, D. Parslow, H. Li, J. M. Gaziano, M. Abe, and J. Ma Prostate Cancer Risk and ESR1 TA, ESR2 CA Repeat Polymorphisms Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2233 - 2236. [Abstract] [Full Text] [PDF]